Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility

Journal of Endocrinology

Volumn 222, Issue 3, 2014, Pages 341-350

  van der Sluis, Ronald J ^a   van den Aardweg, Tim ^a   Reuwer, Anne Q ^b   Twickler, Marcel T ^c   Boutillon, Florence ^d   van Eck, Miranda ^a   Goffin, Vincent ^d   Hoekstra, Menno ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d INSERM   (France)

Author keywords

Atherosclerosis; Del1 9 G129R hPRL; Lipoprotein; Mouse model; Prolactin receptor

Indexed keywords

CHOLESTEROL ESTER; COLLAGEN; CORTICOSTERONE; HORMONE RECEPTOR BLOCKING AGENT; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; PROLACTIN; PROLACTIN, ARG(129)-; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISEASE PREDISPOSITION; GENE EXPRESSION; KNOCKOUT MOUSE; LEUKOCYTE COUNT; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BLOOD; C57BL MOUSE; DEFICIENCY; GENETICS; LEUKOCYTE; LIPID METABOLISM; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; DISEASE SUSCEPTIBILITY; GENE EXPRESSION; LEUKOCYTES; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROLACTIN; RECEPTORS, LDL; RECEPTORS, PROLACTIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84907345929     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0343     Document Type: Article

References (42)

1. ArslanMS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z et al. 2014 Preclinical atherosclerosis in patients with prolactinoma. Endocrine Practice 20 447-451.
2. Berinder K, Nyström T, Höybye C, Hall K & Hulting AL 2011 Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14 199-207.
3. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA & Goffin V 2003 Development of pure prolactin receptor antagonists. Journal of Biological Chemistry 278 35988-35999.
4. Boring L, Gosling J, Cleary M & Charo IF 1998 Decreased lesion formation in CCR2K/K mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 894-897.
5. Bouchard B, Ormandy CJ, Di Santo JP & Kelly PA 1999 Immune system development and function in prolactin receptor-deficient mice. Journal of Immunology 163 576-582.
6. Chang LL, Lo MJ, Kan SF, Huang WJ, Chen JJ, Kau MM, Wang JL, Lin H, Tsai SC, Chiao YC et al. 1999 Direct effects of prolactin on corticosterone release by zona fasciculata-reticularis cells from male rats. Journal of Cellular Biochemistry 73 563-572.
7. Cholesterol Treatment Trialists' (CTT) Collaborators. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, VoyseyM, Gray A, Collins R et al. 2012 The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 581-590.
8. Chomczynski P & SacchiN 1987 Single-stepmethod of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 156-159.
9. Dardenne M, de Moraes Mdo C, Kelly PA & Gagnerault MC 1994 Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry. Endocrinology 134 2108-2114.
10. Dugan AL, Schwemberger S, Noel GJ, Babcock GF, Ogle CK, Buckley DJ, Horseman ND & Gregerson KA 2007 Stress and prolactin effects on bone marrow myeloid cells, serum chemokine and serum glucocorticoid levels in mice. Neuroimmunomodulation 14 287-296.
11. Fahy U, Hopton MI, HartogM, Bolton CH & HullMG 1999 The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Human Reproduction 14 285-287.
12. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, RizosD, Creatsa M, ChristodoulakosG, Alevizaki M, Sfikakis PP et al. 2009 Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54 98-105.
13. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P & Rollins BJ 1998 Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell 2 275-281.
14. Haring R, Friedrich N, Völzke H, Vasan RS, Felix SB, Dörr M, Meyer Zu Schwabedissen HE, Nauck M & Wallaschofski H 2014 Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. European Heart Journal 35 1215-1221.
15. Hoekstra M, Kruijt JK, Van Eck M & Van Berkel TJ 2003 Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. Journal of Biological Chemistry 278 25448-25453.
16. Hoekstra M, Frodermann V, van den Aardweg T, van der Sluis RJ & Kuiper J 2013 Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized APOE knockout mice. PLoS ONE 8 e80441.
17. Hou L, Lloyd-Jones DM, Ning H, Huffman MD, Fornage M, He K, Zhang X, Jacobs DR, Goff DC, Sidney S et al. 2013 White blood cell count in young adulthood and coronary artery calcification in early middle age: coronary artery risk development in young adults (CARDIA) study. European Journal of Epidemiology 28 735-742.
18. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE & Herz J 1993 Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. Journal of Clinical Investigation 92 883-893.
19. Jaroenporn S, Nagaoka K, Ohta R,Watanabe G & Taya K 2007 Direct effects of prolactin on adrenal steroid release in male Hatano high-avoidance (HAA) rats may be mediated through Janus kinase 2 (Jak2) activity. Journal of Reproduction and Development 53 887-893.
20. Jee SH, Park JY, Kim HS, Lee TY & Samet JM 2005 White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. American Journal of Epidemiology 162 1062-1069.
21. Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH & Wang HJ 2014 Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 17 232-239.
22. Li Z, Yu C, Han Y, Ren H, ShiW, Fu C, He D, Huang L, Yang C, Wang X et al. 2008 Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells. American Journal of Physiology. Heart and Circulatory Physiology 294 H2761-H2768.
23. Lo MJ & Wang PS 2003 Relative and combined effects of estradiol and prolactin on corticosterone secretion in ovariectomized rats. Chinese Journal of Physiology 46 103-109.
24. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen- Jones D & Moots RJ 2002 Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. Journal of Neuroimmunology 132 34-40.
25. Meli R, Bentivoglio C, Nuzzo I, Mattace Raso G, Galdiero E, Galdiero M, Di Carlo R & Carratelli CR 2003 Th1-Th2 response in hyperprolactinemic mice infected with Salmonella enterica serovar Typhimurium. European Cytokine Network 14 186-191.
26. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI & Takeshita A 2001 New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103 2096-2101.
27. Peeva E, Michael D, Cleary J, Rice J, Chen X & Diamond B 2003 Prolactin modulates the naive B cell repertoire. Journal of Clinical Investigation 111 275-283.
28. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, Kastelein JJ, Hamann J, Goffin V, von der Thüsen JH et al. 2011 The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? Journal of Endocrinology 208 107-117.
29. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA et al. 2010 Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. PNAS 107 15199-15204.
30. Saha S, Gonzalez J, Rosenfeld G, Keiser H & Peeva E 2009 Prolactin alters the mechanisms of B cell tolerance induction. Arthritis and Rheumatism 60 1743-1752.
31. van der Sluis RJ, van Puijvelde GH, Van Berkel TJ & Hoekstra M 2012 Adrenalectomy stimulates the formation of initial atherosclerotic lesions: reversal by adrenal transplantation. Atherosclerosis 221 76-83.
32. Tong PC, Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN & Chan JC 2004 White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 27 216-222.
33. Touraine P & Kelly PA 1995 Expression of the short and long forms of the prolactin receptor in murine lymphoid tissues. Recent Progress in Hormone Research 50 423-428.
34. Twig G, Afek A, Shamiss A, Derazne E, Tzur D, Gordon B & Tirosh A 2012 White blood cell count and the risk for coronary artery disease in young adults. PLoS ONE 7 e47183.
35. VanderLaan PA, Reardon CA, Thisted RA & Getz GS 2009 VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. Journal of Lipid Research 50 376-385.
36. Van Eck M, HerijgersN, Yates J, PearceNJ,Hoogerbrugge PM, Groot PH&Van Berkel TJ 1997BonemarrowtransplantationinapolipoproteinE-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 17 3117-3126.
37. Van Eck M, Ye D, Hildebrand RB, Kar Kruijt J, de Haan W, Hoekstra M, Rensen PC, Ehnholm C, Jauhiainen M & Van Berkel TJ 2007 Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circulation Research 100 678-685.
38. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M & Van Eck M 2007 Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arteriosclerosis, Thrombosis, and Vascular Biology 27 578-586.
39. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS & Zheng WM 2006 Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. Journal of Neurosurgery 104 54-61.
40. Yang L, Hu Y, Li X, Zhao J & Hou Y 2006 Prolactin modulates the functions of murine spleen CD11c-positive dendritic cells. International Immunopharmacology 6 1478-1486.
41. Yarman S, Kurtulmus N & Bilge A 2012 Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Neuro Endocrinology Letters 33 340-346.
42. Zeng C,WangD, Yang Z,Wang Z, Asico LD,WilcoxCS, EisnerGM,WelchWJ, Felder RA & Jose PA 2004 Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension 43 673-679.